Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$10.37−0.01 (-0.10%)
Close on Nov 19, 2026Market cap $1.33BP/E –Yield –
Generate Biomedicines free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$57.01M | – |
| Q2 FY2026 | Jun 30, 2026 | -$58.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$84.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.66M | – |
| Q2 FY2025 | Jun 30, 2025 | -$48.91M | – |
| Q1 FY2025 | Mar 31, 2025 | -$53.93M | – |
See a number that looks wrong?